Toledo Institute of Clinical Research Inc. | Toledo, OH
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this trial is:
Full description
This trial consists of 3 different periods:
The primary clinical question of interest is what is the effect of remibrutinib treatment versus placebo on the change from baseline in UAS7, ISS7 and HSS7 scores after 12 weeks of treatment
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
100 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Novartis Pharmaceuticals; Novartis Pharmaceuticals
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal